APEX1 and non-small cell lung carcinoma: Indeed, AT-101 enhanced the sensitivity of A549 cells to cisplatin in vitro and in vivo by inhibiting APE1-mediated IL-6/STAT3 signaling activation, suggesting its potential use in NSCLC chemotherapy [194].